Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Service d'aide à la décision clinique

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Volume 60, n° 6
page 333 (décembre 2014)
Doi : 10.1016/j.neuchi.2014.10.033
Réunion de la Société de Neurochirurgie de Langue Française, Montrouge, 7-10 décembre 2014

Non-small cell lung cancer molecular alterations impact on brain metastases response to gamma knife radiosurgery: Identification of potential radiosensitive tumor phenotypes

S. De La Rosa Morilla, R. Faguer, C. Joubert, N. Mansouri, S. Boissonneau, S. Fuentes, H. Dufour, F. Barlesi, J. Regis, P. Metellus
 Marseille, France 

Corresponding author.

Results from clinical studies regarding the radiosensitivity of non-small cell lung cancer (NSCLC) brain metastases (BMs) are scarce and inconclusive. Indeed, little is known about the actual impact of the primary tumor molecular profile and radiological response to radiosurgery. We report here the analysis of a prospective patient cohort of NSCLC patients harboring BMs treated by gamma knife radiosurgery and investigated whether the primary tumor molecular phenotype had an actual impact on BM radiosensitivity.

Materials and methods

Two hundred sixty three patients were enrolled between January 2010 and April 2013. Molecular profile was available for 90 patients. Local and distant brain control was determined for these 90 patients harboring 173 BMs. Radiological assessment using MRI-scans was undertaken every 3 months after radiosurgery. Patient-, tumor- and treatment-related data were included. Log-rank test and Cox regression model were used to correlate molecular profile of the primary tumor and other clinical features to intracranial radiological control.


In total, 48/90 (53.3%) of patients presented molecular alterations, 25/90 (27.8%) had KRAS mutations, 16/90 (17.8%) had EGFR mutations, 3/90 (3.3%) had ALK translocation, and 4 patients other genetic alterations. Overall, local and distant control was achieved in 83/90 (92.2%) and in 39/90 (43.4%) patients respectively. No local treatment failure was observed in EGFR mutant or ALK translocated tumor. One (4%) of the 25 KRAS mutated patients experienced a local failure. In the 42/90 patients (46.7%), local failure occurred in 4 cases (9.5%). Multivariate analysis demonstrated that EGFR mutation status and ALK translocation were independent predictors of better local control in patients treated by gamma knife radiosurgery.


EGFR mutation and ALK translocation are independent prognostic factor regarding local control after Gama Knife radiosurgery in NSCLC patients with BM. The results provided here suggest that molecular profile of NSCLC patient might be taken in account in treatment decision strategy.

The full text of this article is available in PDF format.

© 2014  Published by Elsevier Masson SAS.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline